Board meeting set to approve standalone quarterly results

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.8%Reaction day

₹36.29

prior close

₹36.29

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 171sector+0.5%+1.3% vs sector

On the reaction day the stock moved 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.4

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.8pendingpending+0.5+1.3

Next day

+2.8pendingpending+0.4+2.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

No consolidated results for the quarter ended 30 September 2026 or its year-earlier comparison were included. The board will meet on 14 November 2026 to approve standalone unaudited results for that quarter. The insider trading window is closed from 1 October until 48 hours after the results are announced.

Likely market impact

Routine scheduling notice only. No results or financial figures were released, so there is no clear signal for earnings or the share price.

By the numbers

The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.